EXD2

Across TCGA pan-cancer cohorts, EXD2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EXD2 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher EXD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EXD2 expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

HNSC, PDAC, and CCRCC are the cancer types where EXD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.867	1.000	.007	46	view →
PDAC	DFS	Tertile	All	0.653	0.861	.001	42	view →
CCRCC	DFS	Tertile	IV	0.113	0.948	.024	13	view →
COAD	DFS	Median	All	1.000	0.884	.017	12	view →
GBM	DFS	Median	All	0.236	0.499	.004	2	view →
LUAD	OS	Median	II,III,IV	1.000	0.501	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EXD2–HNSC (DFS)

Open the HNSC breakdown →